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2Background
 Last statement published in 2013, included ACIP recommendations for quadrivalent 
meningococcal conjugate (MenACWY) vaccination.
 Since this time, 5 policy notes related to MenACWY vaccination and recently-licensed 
serogroup B (MenB) vaccines have been published.
 In 2019, an updated statement was developed to consolidate all existing ACIP 
recommendations for MenACWY and MenB vaccines in a single document.
– If ACIP votes to recommend MenB booster doses in persons at increased risk, 
recommendations will be included.
3Objectives of updated statement
 Describe background on meningococcal disease, epidemiology, and risk groups.
 Provide updated information on currently licensed and available vaccines.
 Describe process undertaken and rationale used in support of ACIP recommendations.
 Provide ACIP recommendations and guidance for use of meningococcal vaccines.
4Activities
 Conducted systematic review of the literature related to safety, immunogenicity, and 
effectiveness of MenACWY and MenB vaccines in licensed age groups.
 Consolidated and clarified existing MenACWY and MenB recommendations, and drafted 
preliminary MenB booster recommendations (to be included if voted up by ACIP).
 Draft statement shared with Work Group members and ACIP voting members to provide 
opportunity for feedback prior to today’s meeting.
5Meningococcal vaccines licensed and available in the United States
Note: Two vaccine products no longer available in the US:
Menomune® (Sanofi Pasteur): Polysaccharide quadrivalent (A, C, W, Y) vaccine
MenHibRix® (GlaxoSmithKline): combined Haemophilus influenzae type b and meningococcal conjugate (C, Y) vaccine
Vaccine Abbreviation Type Manufacturer Serogroups Licensed ages
Menactra® MenACWY-D Conjugate – Diphtheria 
toxoid
Sanofi Pasteur A, C, W, Y 9 months—55 years
Menveo® MenACWY-CRM Conjugate – CRM197 GlaxoSmithKline A, C, W, Y 2 months—55 years
Trumenba® MenB-FHbp Protein Pfizer B 10—25 years
Bexsero® MenB-4C Protein GlaxoSmithKline B 10—25 years
6Timeline of licensures and recommendations (2005-2019)
Year Licensures and Recommendations
2005 MenACWY-D licensed and routinely recommended for adolescents and persons aged 11–55 at increased risk .
2006 Children entering high school and persons at increased risk years prioritized due to initial limited vaccine supply.
2007 MenACWY-D recommended for all adolescents aged 11–18 years as well as children aged 2–10 years at increased risk.
2009 MenACWY-D booster dose recommended for persons who remain at increased risk. 
2010 MenACWY-CRM licensed. Booster dose recommended for adolescents aged 16 years, and 2-dose primary series 
recommended for persons with certain underlying medical conditions.
2011 MenACWY-D primary series recommended for children aged 9–23 months at increased risk for meningococcal disease.
2012 Hib-MenCY-TT licensed and primary series recommended for children aged 2–18 months at increased risk.
2013 MenACWY-CRM licensed and primary series recommended for children aged 2–23 months at increased risk for 
meningococcal disease.
2014 MenB-FHbp licensed.
2015 MenB-4C licensed. MenB primary series recommended routinely for persons at increased risk; adolescents aged 16–23 years 
may be vaccinated with MenB vaccine based on individual clinical decision-making.
2016 MenACWY primary series recommended for persons living with HIV.
2017 MenB-FHbp recommendations updated to allow 2-or 3-dose series, depending on indication, following updated licensure. 
Distribution of MPSV4 and Hib-MenCY-TT discontinued in the United States.
2019 MenB booster dose recommendations to be included here if voted upon by ACIP.
7Key changes
 All existing MenACWY and MenB recommendations, as well as the proposed new 
recommendation for MenB booster doses, in a single document.
 Previous ‘Category B’ language for MenB primary vaccination in adolescents updated to 
“ACIP recommends a MenB primary series for individuals aged 16-23 years based on 
shared clinical decision-making”.
 Appendices with guidance for chemoprophylaxis of close contacts and management of 
outbreaks no longer part of ACIP statement.
8Today’s vote
 Affirm updated statement: “Meningococcal Vaccination: Recommendations of the Advisory 
Committee on Immunization Practices”.
Votes
10
Vote #1
 ACIP recommends MenB booster vaccination in persons aged ≥10 years at increased risk 
for serogroup B meningococcal disease who previously completed a MenB primary series.
11
Vote #2
 ACIP affirms the updated statement “Meningococcal Vaccination: Recommendations of the 
Advisory Committee on Immunization Practices”
